Thelansis’s “Merkel Cell Carcinoma (MCC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer associated with Merkel cell polyomavirus in many cases or ultraviolet-induced DNA damage in virus-negative tumours. It often appears as a rapidly enlarging, painless red, pink or violaceous nodule, often on sun-exposed skin. Regional lymph-node spread and distant metastases may occur early. Risk is higher with older age and immunosuppression. Diagnosis is confirmed by skin biopsy and immunohistochemistry, followed by staging. Localised disease is generally treated with surgery and often radiotherapy; sentinel lymph-node evaluation helps guide management. For unresectable or metastatic disease, PD-1/PD-L1 checkpoint inhibitors, including avelumab, pembrolizumab and retifanlimab, have shifted care beyond chemotherapy, which often produces less durable responses. Ongoing trials are testing vaccine-based and immune-combination strategies. Recurrence remains an important risk, making surveillance essential.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Merkel Cell Carcinoma (MCC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Merkel Cell Carcinoma (MCC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.